ASX/Media Release

2022 Annual General Meeting and Key Dates

SYDNEY, AUSTRALIA – 21 September 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2022 Annual General Meeting, (AGM) on Wednesday, 23 November 2022 commencing at 11.00am (AEDT).

Details of the format and the agenda for the AGM will be provided in the Notice of Meeting which is expected to be released next month.

The closing time and date for receipt of director nominations for candidates other than those recommended by the Board is 5:00 pm, Thursday, 29 September 2022.

Any nominations must be received at the Company's registered office no later than 5.00 pm (Sydney time) on Thursday, 29 September 2022.

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Further information can be found on the Company's website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the Board of Immutep Limited.